ArticleGynecology and minimally invasive therapy
Size Does Matter: Long-term Efficacy and Safety of Minimesh in Transvaginal Pelvic Organ Prolapse Repair.
Article in Gynecology and minimally invasive therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Transvaginal single-pathway composite reconstruction for pelvic organ prolapse combined with rectal prolapse: a case report.Frontiers in surgery · 2026Article
- Advances in Pelvic Organ Prolapse Management.Gynecology and minimally invasive therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The Food and Drug Administration banned the use of transvaginal mesh for pelvic organ prolapse (POP) repair due to safety and efficacy concerns. The present study aimed to evaluate the safety and efficacy of a novel lightweight minimesh (SERATOM Materials and Methods: A cohort study of 134 consecutive patients (mean age: 61.7 ± 9.4 years, range: 46-88) who underwent transvaginal minimesh repair (SERATOM Results: The mean duration of surgery and blood loss was 30.8 min and 32.4 ml, respectively. Most patients (98.5%) were discharged on the day of surgery or the day after. There were no significant intra- or early postoperative complications, except for one case of postoperative perineal hematoma that was managed conservatively. Of the initial 134 patients, 110 (82%) were available for long-term follow-up. There were no mesh erosions. Conclusion: Transvaginal SERATOM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.